RegulatoryOfficial

EU and Japan press case for sustained medical countermeasure R&D at Tokyo session

🇪🇺 European Commission (DG SANTE) · Mon 16 Nov 2026

A policy study session hosted by DNDi in Tokyo used dengue as a case study to argue that preparedness depends on research capacity maintained between outbreaks.

The European Commission, Japan and the Drugs for Neglected Diseases initiative (DNDi) used a policy study session in Tokyo on 16 November to stress the value of sustained investment in research and development for medical countermeasures. Laurent Muschel, Deputy Head of DG HERA, attended.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: European Commission (DG SANTE) ↗

Article written by VigiEye from the official source (European Commission (DG SANTE)). AI-assisted; check the source before acting.

More Regulatory All →